MEI Pharma Stock News

Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, and MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advan

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on MEI Pharma (NASDAQ:MEIP) on Monday, setting a price target of $10, which is approximately 264.96% above the present share price of $2.74.

Investors in MEI Pharma, Inc. (NASDAQ:MEIP) had a good week, as its shares rose 3.8% to close at US$2.74 following the...

MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended March 31, 2020 and highli

Stocks Analysis by Harry Boxer covering: Alcoa Corp, Occidental Petroleum Corporation, Apache Corporation, Valero Energy Corporation. Read Harry Boxer's latest article on Investing.com

Unusual call flow in option market yesterday EBAY ZNGA RIO MEIP

If you own shares in MEI Pharma, Inc. (NASDAQ:MEIP) then it's worth thinking about how it contributes to the...

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn't the only way for biotech companies to

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs April 14) Bio-Rad Laboratories, Inc...

Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares rose 59.3% to $7.25 in pre-market trading. Applied DNA has shipped coronavirus LinearDNA vaccine candidates to Italian...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced the appointment of Cheryl L. Cohen to its board of directo